Novo Nordisk | NVO - Ebitda

Stock Price
36.65
Daily Change
0.21 0.58%
Monthly
-0.05%
Yearly
-45.35%
Q2 Forecast
35.05

Novo Nordisk reported DKK31.44B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
Aurora Cannabis CAD 18.48M 3.11M Dec/2025
Bausch Health Companies USD 986M 74M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 4.77B 1.11B Dec/2025
Novo Nordisk DKK 37.3B 5.86B Dec/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pacira USD 38.71M 10.65M Dec/2025
Perrigo USD 258.8M 37.3M Sep/2025
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 90.82M 3.99M Dec/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Supernus Pharmaceuticals USD 48.5M 6.6M Dec/2025
Zoetis USD 1.04B 87M Sep/2025